Rigel has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to ...
Tris Pharma has reported positive outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol to treat moderate-to-severe ...
Intellia aims to submit a biologics license application in 2026. Credit: Piotr Swat/Shutterstock. Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback